Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03706079




Registration number
NCT03706079
Ethics application status
Date submitted
11/10/2018
Date registered
15/10/2018
Date last updated
6/06/2023

Titles & IDs
Public title
Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma
Scientific title
A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (DESTINATION)
Secondary ID [1] 0 0
D5180C00018
Universal Trial Number (UTN)
Trial acronym
DESTINATION
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Asthma 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Asthma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Tezepelumab
Other interventions - Placebo

Experimental: Tezepelumab - Tezepelumab subcutaneous injection

Placebo Comparator: Placebo - Placebo: Placebo subcutaneous injection


Other interventions: Tezepelumab
Tezepelumab subcutaneous injection

Other interventions: Placebo
Placebo subcutaneous injection
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Exposure Adjusted Incidence Rates of AEs/SAEs
Timepoint [1] 0 0
Baseline (Week 0 in predecessor study) to Week 104. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.
Primary outcome [2] 0 0
Total Time at Risk
Timepoint [2] 0 0
Baseline (Week 0 in predecessor study) to Week 104. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.
Secondary outcome [1] 0 0
Annualized Asthma Exacerbation Rate (AAER)
Timepoint [1] 0 0
Baseline (Week 0 in predecessor study) to Week 104. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.

Eligibility
Key inclusion criteria
- Provision of signed and dated written informed consent

- Negative urine test for female subjects of childbearing potential prior to
administration of IP at visit 1

- Females of childbearing potential who are sexually active with a nonsterilized male
partner must use a highly effective method of contraception from screening, and must
agree to continue using such precautions for 16 weeks after the final dose of IP.

- Female or male subjects who have not met investigational product discontinuation
criteria and have attended the EOT visit in either study D5180C00007 (NAVIGATOR) or
D5180C00009 (SOURCE)

To enter the extended follow-up phase of the study, the following inclusion criteria also
apply:

- Provision of signed and dated Addendum for Extended Follow-up to informed consent, as
well as assent by adolescent subjects where applicable, prior to any mandatory study
specific procedures, sampling and analyses before Extended Follow Up.

- Must have entered DESTINATION from D5180C00007 study and have completed IP dosing to
Week 100, have not met IP Discontinuation criteria and have attended the EOT Visit.
Minimum age
13 Years
Maximum age
81 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Any clinically important pulmonary disease other than asthma

- Any disorder, including, but not limited to cardiovascular, gastrointestinal, hepatic,
renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological,
psychiatric, or major physical impairment that is not stable

- History of chronic alcohol or drug abuse within 12 months prior to visit 1

- Current malignancy or malignancy that developed during a predecessor study

- Major surgery or planned surgical procedures requiring general anesthesia or inpatient
status for > 1 day during the conduct of the study

- Treatment with systemic immunosuppressive/immunomodulating drugs except for OCS used
in the treatment of asthma/asthma exacerbations within the last 12 weeks prior to
randomization

- Concurrent enrolment in another clinical study involving an IP

- Any clinically meaningful abnormal finding in physical examination, vital signs,
ECG,haematology, clinical chemistry, or urinalysis during the predecessor study

- Pregnant, breastfeeding, or lactating

To enter the extended follow-up phase of the study (which extends from week 104 to week
140), the following exclusion criteria also apply:

- Discontinuation of IP during the treatment period of DESTINATION.

- Entered DESTINATION from D5180C00009 (SOURCE) study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
7/01/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
18/05/2022
Sample size
Target
Accrual to date
Final
951
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Kent Town
Recruitment hospital [2] 0 0
Research Site - Melbourne
Recruitment hospital [3] 0 0
Research Site - New Lambton
Recruitment hospital [4] 0 0
Research Site - Spearwood
Recruitment hospital [5] 0 0
Research Site - Westmead
Recruitment hospital [6] 0 0
Research Site - Woolloongabba
Recruitment postcode(s) [1] 0 0
5067 - Kent Town
Recruitment postcode(s) [2] 0 0
3004 - Melbourne
Recruitment postcode(s) [3] 0 0
2310 - New Lambton
Recruitment postcode(s) [4] 0 0
6163 - Spearwood
Recruitment postcode(s) [5] 0 0
2145 - Westmead
Recruitment postcode(s) [6] 0 0
4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Idaho
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
Nebraska
Country [13] 0 0
United States of America
State/province [13] 0 0
Nevada
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oklahoma
Country [19] 0 0
United States of America
State/province [19] 0 0
Oregon
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
South Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Virginia
Country [24] 0 0
United States of America
State/province [24] 0 0
Wisconsin
Country [25] 0 0
Argentina
State/province [25] 0 0
Buenos Aires
Country [26] 0 0
Argentina
State/province [26] 0 0
Caba
Country [27] 0 0
Argentina
State/province [27] 0 0
Ciudad de Buenos Aires
Country [28] 0 0
Argentina
State/province [28] 0 0
Córdoba
Country [29] 0 0
Argentina
State/province [29] 0 0
Mendoza
Country [30] 0 0
Argentina
State/province [30] 0 0
Nueve de julio
Country [31] 0 0
Argentina
State/province [31] 0 0
Quilmes
Country [32] 0 0
Argentina
State/province [32] 0 0
San Fernando
Country [33] 0 0
Argentina
State/province [33] 0 0
San Miguel de Tucuman
Country [34] 0 0
Austria
State/province [34] 0 0
Wien
Country [35] 0 0
Brazil
State/province [35] 0 0
Blumenau
Country [36] 0 0
Brazil
State/province [36] 0 0
Botucatu
Country [37] 0 0
Brazil
State/province [37] 0 0
Curitiba
Country [38] 0 0
Brazil
State/province [38] 0 0
Porto Alegre
Country [39] 0 0
Brazil
State/province [39] 0 0
Recife
Country [40] 0 0
Brazil
State/province [40] 0 0
Salvador
Country [41] 0 0
Brazil
State/province [41] 0 0
Santo Andre
Country [42] 0 0
Brazil
State/province [42] 0 0
Sao Bernardo do Campo
Country [43] 0 0
Brazil
State/province [43] 0 0
Sorocaba
Country [44] 0 0
Canada
State/province [44] 0 0
Alberta
Country [45] 0 0
Canada
State/province [45] 0 0
Ontario
Country [46] 0 0
Canada
State/province [46] 0 0
Quebec
Country [47] 0 0
France
State/province [47] 0 0
Brest Cedex 2
Country [48] 0 0
France
State/province [48] 0 0
Le Kremlin-Bicêtre
Country [49] 0 0
France
State/province [49] 0 0
Lyon Cedex 04
Country [50] 0 0
France
State/province [50] 0 0
Marseille Cedex 20
Country [51] 0 0
France
State/province [51] 0 0
Montpellier
Country [52] 0 0
France
State/province [52] 0 0
Nantes
Country [53] 0 0
France
State/province [53] 0 0
Paris
Country [54] 0 0
France
State/province [54] 0 0
Pessac
Country [55] 0 0
France
State/province [55] 0 0
Strasbourg Cedex
Country [56] 0 0
Germany
State/province [56] 0 0
Bamberg
Country [57] 0 0
Germany
State/province [57] 0 0
Berlin
Country [58] 0 0
Germany
State/province [58] 0 0
Frankfurt am Main
Country [59] 0 0
Germany
State/province [59] 0 0
Frankfurt
Country [60] 0 0
Germany
State/province [60] 0 0
Hamburg
Country [61] 0 0
Germany
State/province [61] 0 0
Hannover
Country [62] 0 0
Germany
State/province [62] 0 0
Koblenz
Country [63] 0 0
Germany
State/province [63] 0 0
Landsberg
Country [64] 0 0
Germany
State/province [64] 0 0
Leipzig
Country [65] 0 0
Germany
State/province [65] 0 0
Lübeck
Country [66] 0 0
Germany
State/province [66] 0 0
Mainz
Country [67] 0 0
Israel
State/province [67] 0 0
Ashkelon
Country [68] 0 0
Israel
State/province [68] 0 0
Haifa
Country [69] 0 0
Israel
State/province [69] 0 0
Jerusalem
Country [70] 0 0
Israel
State/province [70] 0 0
Kfar Saba
Country [71] 0 0
Israel
State/province [71] 0 0
Rehovot
Country [72] 0 0
Korea, Republic of
State/province [72] 0 0
Bucheon-si
Country [73] 0 0
Korea, Republic of
State/province [73] 0 0
Cheongju-si
Country [74] 0 0
Korea, Republic of
State/province [74] 0 0
Daegu
Country [75] 0 0
Korea, Republic of
State/province [75] 0 0
Jeju-do
Country [76] 0 0
Korea, Republic of
State/province [76] 0 0
Jeonju-si
Country [77] 0 0
Korea, Republic of
State/province [77] 0 0
Seongnam-si
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Seoul
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Suwon-si
Country [80] 0 0
Poland
State/province [80] 0 0
Kraków
Country [81] 0 0
Poland
State/province [81] 0 0
Wroclaw
Country [82] 0 0
Poland
State/province [82] 0 0
Lódz
Country [83] 0 0
Russian Federation
State/province [83] 0 0
Izhevsk
Country [84] 0 0
Russian Federation
State/province [84] 0 0
Moscow
Country [85] 0 0
Russian Federation
State/province [85] 0 0
St-Petersburg
Country [86] 0 0
Saudi Arabia
State/province [86] 0 0
Jeddah
Country [87] 0 0
South Africa
State/province [87] 0 0
Bellville
Country [88] 0 0
South Africa
State/province [88] 0 0
Cape Town
Country [89] 0 0
South Africa
State/province [89] 0 0
Durban
Country [90] 0 0
South Africa
State/province [90] 0 0
Johannesburg
Country [91] 0 0
South Africa
State/province [91] 0 0
Lenasia Ext8
Country [92] 0 0
South Africa
State/province [92] 0 0
Meadowdale, Germiston
Country [93] 0 0
South Africa
State/province [93] 0 0
Middelburg
Country [94] 0 0
South Africa
State/province [94] 0 0
Parow
Country [95] 0 0
South Africa
State/province [95] 0 0
Umkomaas
Country [96] 0 0
Taiwan
State/province [96] 0 0
Kaohsiung
Country [97] 0 0
Taiwan
State/province [97] 0 0
Taichung
Country [98] 0 0
Taiwan
State/province [98] 0 0
Taipei
Country [99] 0 0
Turkey
State/province [99] 0 0
Ankara
Country [100] 0 0
Turkey
State/province [100] 0 0
Bursa
Country [101] 0 0
Turkey
State/province [101] 0 0
Istanbul
Country [102] 0 0
Ukraine
State/province [102] 0 0
Dnipro
Country [103] 0 0
Ukraine
State/province [103] 0 0
Ivano-Frankivsk
Country [104] 0 0
Ukraine
State/province [104] 0 0
Kharkiv Region
Country [105] 0 0
Ukraine
State/province [105] 0 0
Kherson
Country [106] 0 0
Ukraine
State/province [106] 0 0
Lutsk
Country [107] 0 0
Ukraine
State/province [107] 0 0
Vinnytsia
Country [108] 0 0
Vietnam
State/province [108] 0 0
Ha Noi
Country [109] 0 0
Vietnam
State/province [109] 0 0
Hanoi
Country [110] 0 0
Vietnam
State/province [110] 0 0
Ho Chi Minh

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AstraZeneca
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Amgen
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Subjects who completed either D5180C00007 or D5180C00009 will be offered the opportunity to
consent for the Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group,
Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in
Adults and Adolescents with Severe Uncontrolled Asthma. The study consists of a treatment
phase, followed by a follow-up phase where subjects will not receive IP. The length of the
follow up phase is determined by which study the subject had previously completed.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03706079
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Andrew Menzies-Gow, MD
Address 0 0
Royal Brompton Hospital, United Kingdom
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03706079